UT MD Anderson· @UTMDAnderson · X·· 2026-04-19Score60
Reading
Immunotherapy: CAR-T in solid tumors, mRNA vaccines, TCR-T
局部 nivolumab · Oral pre-cancer clinical response 85%, 1-year clearance 82%
Body
Based on the initial results from the CheckMate 77T trial,
@us_fda
approved perioperative nivolumab for the treatment of resectable non-small cell lung cancer in 2024.
At #AACR26, Dr. Tina Cascone presented additional findings derived from biomarker analyses. (1/2)
Heat 16 · 12 likes · 1 reply · 3 reposts
Conference abstracts
Justine Panian, Lin Liu, Minya Pu, Emily Pittman, Samuel Pena, Archana Ajmera, Yu-Wei Chen, Christos Kyriakopoulos, Qian Qin, James Michael Randall, Tian Zhang, Joshua Michael Lang, Akash Patnaik, Rana R. McKay
Read the abstract →Source: UT MD Anderson · x.com